Work

A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.3103

Authors: Alison L. Raybould, Brian Burgess, Clarissa Urban, Rashid Naim, Michael Sangmin Lee, Autumn Jackson McRee

Institutions: UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3166699257

Cites:

Cited by: 8

Related to: 10